$PSNL

Hall Christopher M sold $1.3M of PSNL

Hall Christopher M (Chief Executive Officer) sold 100,000 shares of Personalis, Inc. (PSNL) at $13.15 ($1.32M total) on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hall Christopher M
Published Jun 26, 2026, 11:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 11:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PSNL
Neutral
medium confidence
Mentioned
$PSNL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PSNLNeutralLow
01

Why it matters

The CEO’s open-market sale reduces insider holdings but is scheduled via a 10b5-1 plan, typically lowering the signal-to-noise for directional trading.

02

Market read

Traders may monitor PSNL for any follow-on insider activity, but this disclosure alone is unlikely to drive a major repricing.

03

What to watch

The filing does not disclose reasons for the sale; traders should avoid over-weighting insider-sale narratives without corroborating fundamentals or guidance changes.

Relevance 5/10Novelty 5/10Timing: filed after-hours on 2026-06-26 (SEC EDGAR Form 4)

Background

The article is an SEC Form 4 insider transaction for Personalis, Inc. (PSNL).

Company-level read

Ticker impact

$PSNLNeutralMedium confidence
Context

PSNL CEO Christopher M. Hall sold 100,000 shares on 2026-06-26 at $13.15/share under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect is more sentiment/flow-driven than fundamental.

Evidence & confidence

The filing is a primary Form 4 disclosure and the sale size is moderate, but the presence of a pre-arranged 10b5-1 plan reduces interpretive weight versus discretionary selling.

Market effects

No sector-level read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Personalis, Inc.

    Company whose CEO filed the Form 4 insider sale.

  • Christopher M. Hall

    CEO and director who sold shares.

  • 10b5-1 plan

    Pre-arranged plan that schedules insider trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

$PSNLMed

Personalis (PSNL) Has Investors Asking A Fresh Question

Personalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

$TEMHighAI 9/10

Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant

Tempus AI agreed to acquire Personalis for $1.5B in July 2026. Personalis' tech supports Moderna and Merck's mRNA cancer vaccine, which showed positive Phase 3 results in August 2026. Tempus shares rose 23.91% on the news. Personalis' revenue grew 441.6% YoY in Q2 2026. Tempus reported $382.5M in Q2 2026 revenue, up 22% YoY. The deal is expected to close late Q4 2026 or early 2027.